Charlie Harper
Footballguy
Sub $3.
The support level has now become the resistance level.Sub $3.
Couldn’t agree more with your last sentence. Much love for @chet and what he turned us on too. Super grateful. Still very curious about his thoughts on the last few weeks events though.Chet is driving his new Ferrari to the club, if he's still in more than 20% or so I would be surprised......he made some nice coin. Mad a lot of us some money, much appreciated.![]()
Is this from the call today or speculation?“World class" virologist Bruce Patterson had his paper rejected for publication.
Is this what you are referring to?From the call
Nope. There was multiple bad Patterson news.Is this what you are referring to?
FDA did not accept Dr. BP's data on the CCR5 receptor occupancy test for the HIV monotherapy.
Thanks. Is there a recap of the call somewhere? I looked but couldn’t find anythingFrom the call
This came from the Yahoo board.So the interim analysis is being done as we speak?
Anyone know what's the MOST numbers of deaths from LL to still reach a significant p value from the 45?
I haven't seen a summary, yet. If I see one, I'll post it.Thanks. Is there a recap of the call somewhere? I looked but couldn’t find anything
I can post it:I haven't seen a summary, yet. If I see one, I'll post it.
What is the story here? This has always been a red flag for me. They were talking about that paper being published in late April."World class" virologist Bruce Patterson had his paper rejected for publication.
From IHub:
I was most afraid that there would be an insufficient number of deaths.
With that many deaths, there is a chance for this to be significant. Even if not quite significant enough to get EUA, it should hopefully broadcast to the critics that the drug does work. Of course the data won't be released so we won't know until the trial is over.This came from the Yahoo board.
If death is 20 in placebo, L is 25, p=0.03, placebo death rate is 30.77%, L is 19.23%
If death is 19 in placebo, L is 26, p=0.08, placebo death rate is 29.23%, L is 20.00%
If death is 18 in placebo, L is 27, p=0.19, placebo death rate is 27.69%, L is 20.77%
If death is 17 in placebo, L is 28, p=0.38, placebo death rate is 26.15%, L is 21.54%
Did I hear correctly, Nadar will send a copy of the M/M Topline Report to anyone who emails him and requests it?
Golf Guy bannedChet did more than his job a long time back and definitely thanks for turning us onto it. He seems to have Irish Goodbyed though so I'm going to take that as a sign of that he has exited entirely.
Also not seeing Golf Guy much either, perhaps he is gone now too.
you wanna bet now?Did I hear correctly, Nadar will send a copy of the M/M Topline Report to anyone who emails him and requests it?
Let me know if anyone receives a copy.
We know there are 45 deaths in the severe critical trial, we just don't know which arm has what portion. Its enough deaths that it could be statistically significant if leronlimab is a lot better.I'm too drunk, what happened?
All good points, my biggest one i made earlier was why was Patterson only one on board.We know there are 45 deaths in the severe critical trial, we just don't know which arm has what portion. Its enough deaths that it could be statistically significant if leronlimab is a lot better.
Other than that, I don't think the call went great. No mention of a Nasdaq uplist yet. NP does say again that he's 100% sure that they will eventually be approved for HIV but its hard to believe anything from him at face value.
Something about Patterson's paper being rejected which Im trying to get more details on. Doesn't sound good though.
sell those 35k and build me a poker room on the mountain home.All good points, my biggest one i made earlier was why was Patterson only one on board.
But as to my position on this stock. I was 100% up front. I sold, everyone knew. I bought a mountain home with the proceeds. Everyone knows. I got 35k shares. Everyone knows.
I have been skeptical of everything during this and transparent.
Looks like that's about all they will be worth. Bring your own play chips.sell those 35k and build me a poker room on the mountain home.
If they are anywhere near significant, they will release the news and take a fine if needed.With that many deaths, there is a chance for this to be significant. Even if not quite significant enough to get EUA, it should hopefully broadcast to the critics that the drug does work. Of course the data won't be released so we won't know until the trial is over.
Still don't think I want to be holding all my shares into this event but there is some reason to be slightly optimistic
The fine is a penalty on their data and they wont know if significant or not. You think they would do that?If they are anywhere near significant, they will release the news and take a fine if needed.
We are smack dab in the middle of a good old-fashioned cat fightFrom Bruce Peterson.
https://twitter.com/brucep13/status/1311479186645757957
Been doing CCR5 Receptor Occupancy since 1999 for the likes of Pfizer and Schering Plough and soon 2 others. Just went through due diligence with MDBio! Our record stands!!! #incelldx
@brucep13
6:32 PM · Sep 30, 2020·Twitter for iPhone
This is from another board:What is the story here? This has always been a red flag for me. They were talking about that paper being published in late April.
FWIWI heard Dr Bruce Patterson talk about why his paper was rejected.
There were no control patients.
So Dr Patterson connected with other doctors who had treated critically ill Covid-19 patients that could be classified as controls. Analyzing their tissues/blood samples was then done. Then the manuscript had to be rewritten and resubmitted.
This accounts for at least part of the delay in publication.
As a scientist, it is my experience that controls are always required for publication of scientific work.
Here is the original preprint:
https://www.medrxiv.org/content/10.1101/2020.05.02.20084673v1
There are no control patients.
A part of the Abstract is here:
"Here, in 10 terminally-ill, critical COVID-19 patients we report profound elevation of plasma IL-6 and CCL5 (RANTES), decreased CD8+ T cell levels, and SARS-CoV-2 plasma viremia. Following compassionate care treatment with the CCR5 blocking antibody leronlimab, we observed complete CCR5 receptor occupancy on macrophage and T cells, rapid reduction of plasma IL-6, restoration of the CD4/CD8 ratio, and a significant decrease in SARS-CoV-2 plasma viremia. Consistent with reduction of plasma IL-6, single-cell RNA-sequencing revealed declines in transcriptomic myeloid cell clusters expressing IL-6 and interferon-related genes. These results demonstrate a novel approach to resolving unchecked inflammation, restoring immunologic deficiencies, and reducing SARS-CoV-2 plasma viral load via disruption of the CCL5-CCR5 axis, and support randomized clinical trials to assess clinical efficacy of leronlimab-mediated inhibition of CCR5 for COVID-19."
A p value below .005 is going to be very difficult to achieve if the above numbers are true:They are saying a p value lower than .005 will be necessary. To achieve a p value lower than .005, the LL arm would have 20 deaths and the placebo arm would have 25 deaths. This would result in a p value of 0.00349.
This came from the CDC, not CYDY (CYDY reported it as the reason they were being delayed). The cat fight is between BP and the CDC. Weird, because he seems like he's one of the experts on Rantes and CCR5.We are smack dab in the middle of a good old-fashioned cat fight
Definitely. I'm beginning to think the bar is so high for this company that FDA approval will not come. They are more likely to get approval offshore. If there p-value is below .05, they should be shouting that out to the world.The fine is a penalty on their data and they wont know if significant or not. You think they would do that?
That is assuming what Nader said is accurate when he threw Bruce under the bus. Bruce didn't specify the target of his tweet.This came from the CDC, not CYDY (CYDY reported it as the reason they were being delayed). The cat fight is between BP and the CDC. Weird, because he seems like he's one of the experts on Rantes and CCR5.
I don't think he would outright lie when the information is out there. I am suspect that they will ever be granted approval for anything. whether it's written instructions on needle packaging, we want to see safety in 700mg's not 350mg's, or BP (one of the scientific leaders in Rantes) has screwed up the CCR5 receprot occupancy test, despite doing it properly for several other big pharma companies in the past.That is assuming what Nader said is accurate when he threw Bruce under the bus. Bruce didn't specify the target of his tweet.
It might be how they normally do things. They don't usually want to stop a trial before it is completed. So it makes sense that the p value would have to be much better than .05 to end a trial with the interim analysis. But we are in desperate times so I don't think anyone knows.I have been in this long, so I will hold until I see the CD12 results. There is no way they would try and hold them to a p-value of .005. I think that's nonsense.
Do you really believe that Don?Below is a link to Investors Hangout where someone made p value charts. He seems more credible than the other people trying to do p values. To get a p value less than .05, the LL arm would have 23 deaths and the placebo arm would have 22 deaths. That would produce a p value of .03447. However, some people on the boards are saying that a p value of .05 will not be good enough to have the trial stopped for efficacy. They are saying a p value lower than .005 will be necessary. To achieve a p value lower than .005, the LL arm would have 20 deaths and the placebo arm would have 25 deaths. This would result in a p value of 0.00349. Obviously, we are in unique times and no excellent treatment exists so what p value will be necessary is anyone's guess.
https://investorshangout.com/post/view?id=5914267
I'm just the messenger. I have no idea.Do you really believe that Don?
We are talking about a primary endpoint of death. It's nonsense to think you would need to hit anything close to .005. That's just doomsayers talking.It might be how they normally do things. They don't usually want to stop a trial before it is completed. So it makes sense that the p value would have to be much better than .05 to end a trial with the interim analysis. But we are in desperate times so I don't think anyone knows.